Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Dalal

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancerAndrew X Zhu, Richard S Finn, Mary Mulcahy, et al.
The Journal of Surgical Research|June 4, 2013
Intentional foreign object ingestions: need for endoscopy and surgeryPoorvi P Dalal, Andrew J Otey, Emily A McGonagle, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 27, 2019
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 studyYung-Jue Bang, Yoon-Koo Kang, Daniel V Catenacci, et al.
JAMA Oncology|March 16, 2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 TrialCharles S Fuchs, Toshihiko Doi, Raymond W Jang, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancerAndrew X Zhu, Richard S Finn, Mary Mulcahy, et al.
The Journal of Surgical Research|June 4, 2013
Intentional foreign object ingestions: need for endoscopy and surgeryPoorvi P Dalal, Andrew J Otey, Emily A McGonagle, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 27, 2019
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 studyYung-Jue Bang, Yoon-Koo Kang, Daniel V Catenacci, et al.
JAMA Oncology|March 16, 2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 TrialCharles S Fuchs, Toshihiko Doi, Raymond W Jang, et al.
Pageof 6